+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Psoriasis Therapeutics Market by Therapeutic Class, Route of Administration, Distribution Channel, End User, Disease Severity, Patient Age Group - Global Forecast to 2030- Product Image
Psoriasis Therapeutics Market by Therapeutic Class, Route of Administration, Distribution Channel, End User, Disease Severity, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Psoriasis Therapeutics Market by Therapeutic Class, Route of Administration, Distribution Channel, End User, Disease Severity, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968898
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Psoriasis Therapeutics Market grew from USD 23.71 billion in 2024 to USD 26.08 billion in 2025. It is expected to continue growing at a CAGR of 9.81%, reaching USD 41.59 billion by 2030.

Opening the Door to New Horizons in Psoriasis Therapeutics

Psoriasis has emerged as a focal point of innovation within dermatology, driven by groundbreaking scientific discoveries and shifting patient expectations. This executive summary provides a concise yet thorough overview of the current psoriasis therapeutics ecosystem, charting developments in treatment modalities, regulatory dynamics, and market forces. It aims to equip decision-makers with a clear understanding of industry trends, emerging challenges, and strategic opportunities in the context of an increasingly complex healthcare environment.

Our analysis begins by exploring the most disruptive shifts reshaping treatment paradigms and continues through an examination of tariff impacts, segmentation insights, regional trends, leading corporate strategies, and actionable recommendations. By synthesizing diverse data sources and expert perspectives, this summary delivers a coherent narrative to inform strategic planning, investment decisions, and market positioning. It is designed for executives, clinicians, and investors seeking authoritative guidance on harnessing innovation and addressing unmet needs in psoriasis care.

Revolutionizing Treatment Paradigms with Innovation and Integration

Over the past decade, psoriasis treatment has undergone a metamorphosis driven by advances in immunology, patient-centric care models, and digital health integration. The advent of novel biologic agents targeting specific interleukins has replaced broad-spectrum immunosuppression, delivering unprecedented efficacy and safety profiles. Concurrently, small molecule inhibitors and next-generation topical formulations have expanded treatment options across the spectrum of disease severities, empowering personalized regimens.

Digital platforms and telemedicine have further transformed patient engagement, enabling remote monitoring of disease activity and adherence. Health systems are investing in integrated care pathways that bridge dermatology, rheumatology, and primary care, reflecting a holistic approach to management. Regulatory agencies have responded with expedited approval processes for breakthrough therapies, catalyzing faster market entry and intensifying competition. This convergence of scientific innovation, regulatory agility, and patient empowerment is redefining the competitive landscape and driving the next wave of growth in psoriasis therapeutics.

Assessing the Financial Ripple Effects of New US Tariff Policies

The United States’ tariff revisions for 2025 have introduced new cost variables that are reshaping supply chain dynamics and pricing strategies. With raw material levies escalating input costs for biologic and small molecule manufacturers, producers are re-evaluating their manufacturing footprints and sourcing agreements. These additional duties have prompted some global suppliers to shift production to tariff-exempt regions or to optimize formulations to reduce reliance on high-tariff components.

Reimbursement frameworks have adapted, with payers recalibrating formularies to balance cost containment and clinical value. These changes have intensified pressure on pricing negotiation and patient co-pay structures. Manufacturers are responding with targeted patient assistance programs and value-based contracting to mitigate financial barriers. The cumulative effect of these tariff adjustments is a heightened focus on supply chain resilience, cost management, and collaborative pricing models that align stakeholder incentives across the commercial continuum.

Unveiling Deep-Dive Segmentation for Strategic Precision

The psoriasis therapeutics market exhibits nuanced dynamics when viewed through multiple segmentation lenses. Treatment class differentiation spans biologic agents subdivided into IL-12/23, IL-17, IL-23, and TNF inhibitors alongside phototherapy modalities such as excimer laser, narrowband UVB, and PUVA, complemented by small molecule therapies including JAK and PDE4 inhibitors, and a range of topical options from calcineurin inhibitors to corticosteroids and vitamin D analogues. Each class presents distinct clinical profiles and adoption trajectories, reflecting physician preferences and reimbursement criteria.

Administration routes further refine market insights. Injectable therapies, delivered via auto-injectors, pre-filled syringes, or vials, dominate moderate to severe segments, while oral capsules and tablets are gaining traction for their convenience. Topical formulations, encompassing creams, gels, and ointments, continue to serve mild to moderate cases. Distribution channels span hospital, retail, and specialty pharmacies, with specialty venues offering home delivery and in-clinic dispensing to enhance adherence. End users range from clinics and dermatology centers to secondary and tertiary hospitals, each with unique procurement processes and treatment protocols. Disease severity segmentation differentiates mild, moderate, and severe patient cohorts, guiding product positioning and support programs. Patient age group delineation between adult and pediatric populations underscores the importance of tailored dosing, safety monitoring, and caregiver education.

Mapping Regional Dynamics Shaping Psoriasis Therapy Adoption

Regional performance in the psoriasis therapeutics space reflects a blend of epidemiological trends, healthcare expenditure, and regulatory environments. The Americas continue to lead in uptake of high-cost biologics, driven by robust reimbursement frameworks and established specialty pharmacy networks. North American payers are increasingly open to outcome-based contracts, fostering pilot programs that tie payment to patient response.

In Europe, Middle East and Africa, diverse regulatory landscapes and variable healthcare budgets shape access pathways. Western European markets exhibit steady adoption of advanced therapies under centralized health technology assessments, whereas emerging economies prioritize cost-effective generics and biosimilars. Asia-Pacific is characterized by rapid expansion in patient awareness and healthcare infrastructure investment. Markets such as Japan and South Korea demonstrate high penetration of phototherapy and small molecule agents, while Southeast Asia remains underpenetrated, offering significant growth potential as government initiatives expand coverage and negotiate favorable pricing.

Navigating a Competitive Ecosystem of Established Leaders and Biotech Innovators

The competitive landscape is marked by a handful of established innovators leading with advanced biologic platforms, alongside a rising cohort of biotechnology firms focused on next-generation mechanisms of action and delivery innovations. Leading pharmaceutical companies have solidified their positions through extensive clinical development pipelines, targeted acquisitions, and strategic partnerships that bolster their immunology portfolios.

Smaller biotech enterprises are challenging incumbents with novel candidates in early-phase trials, exploring combination regimens and precision biomarkers to optimize patient selection. Collaborations between large pharmaceutical firms and biotech startups have accelerated the translation of breakthrough science into clinical assets. Academic institutions and contract research organizations are playing pivotal roles in generating real-world evidence to support label expansions and market access negotiations. This dynamic interplay between legacy players and agile newcomers is intensifying clinical differentiation and fueling a competitive arms race in psoriasis therapeutics.

Charting a Path to Sustainable Growth and Clinical Differentiation

To capitalize on emerging trends, industry leaders must adopt a multi-faceted strategy. First, investment in digital health tools and teledermatology platforms will be essential to enhance patient engagement, improve adherence, and generate real-world outcomes data that support value-based care models. Second, forging outcomes-driven partnerships with payers and healthcare systems can anchor premium pricing while demonstrating tangible improvements in quality of life and total cost of care.

Third, prioritizing flexible manufacturing strategies-including regional production hubs and modular facilities-will mitigate tariff risks and streamline supply chains. Fourth, expanding clinical trial diversity by including pediatric and underrepresented populations will unlock new indications and strengthen market positioning. Fifth, accelerating the development of combination therapies and innovative delivery systems can address unmet needs in refractory cases. By integrating these approaches, stakeholders can foster resilient growth, differentiate their portfolios, and deliver sustained value to patients and payers alike.

Employing Rigorous Multi-Source Research for In-Depth Insights

This analysis draws upon a comprehensive, multi-source research framework that integrates primary and secondary methodologies. Extensive interviews with dermatologists, payers, contract manufacturers, and patient advocacy leaders provided qualitative insights into evolving treatment preferences, access barriers, and emerging clinical data. Secondary sources included peer-reviewed journals, regulatory filings, company presentations, and proprietary reimbursement databases to validate therapeutic efficacy, market access trends, and pricing structures.

Quantitative data were synthesized from healthcare utilization statistics, distribution channel audits, and real-world evidence repositories to ensure robustness in segmentation and regional analysis. A rigorous validation process reconciled conflicting data points and triangulated findings across stakeholder perspectives. Expert advisory panels reviewed preliminary conclusions to enhance objectivity and refine strategic recommendations. This layered approach ensures that the insights presented are grounded in current industry realities, offering decision-makers a reliable foundation for strategy development.

Synthesizing Insights for Strategic Alignment and Future Growth

As psoriasis therapeutics continue to evolve, the intersection of scientific breakthroughs, policy shifts, and patient engagement imperatives will dictate the next phase of market expansion. The trajectory toward precision immunomodulation, underpinned by advanced biologics and innovative small molecules, promises to elevate standards of care. However, stakeholders must remain vigilant to regulatory changes, tariff impacts, and competitive pressures.

By leveraging deep segmentation insights and regional nuances, and by embracing digital health and real-world evidence, companies can navigate complexities and seize growth opportunities. The recommendations outlined herein offer a strategic blueprint for aligning R&D, commercial operations, and stakeholder partnerships. As the landscape matures, sustained collaboration across the value chain will be pivotal in delivering improved outcomes and driving long-term success in the psoriasis therapeutics arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Class
    • Biologics
      • IL-12/23 Inhibitors
      • IL-17 Inhibitors
      • IL-23 Inhibitors
      • TNF Inhibitors
    • Phototherapy
      • Excimer Laser
      • Narrowband Uvb
      • Puva
    • Small Molecules
      • JAK Inhibitors
      • PDE4 Inhibitors
    • Topicals
      • Calcineurin Inhibitors
      • Corticosteroids
      • Vitamin D Analogues
  • Route Of Administration
    • Injectable
      • Auto-Injector
      • Pre-Filled Syringe
      • Vial
    • Oral
      • Capsule
      • Tablet
    • Topical
      • Cream
      • Gel
      • Ointment
  • Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
    • Specialty Pharmacy
      • Home Delivery
      • In-Clinic Dispensing
  • End User
    • Clinics
    • Dermatology Centers
    • Hospitals
      • Secondary
      • Tertiary
  • Disease Severity
    • Mild
    • Moderate
    • Severe
  • Patient Age Group
    • Adult
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Eli Lilly and Company
  • Pfizer Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Incyte Corporation
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Psoriasis Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. Biologics
8.2.1. IL-12/23 Inhibitors
8.2.2. IL-17 Inhibitors
8.2.3. IL-23 Inhibitors
8.2.4. TNF Inhibitors
8.3. Phototherapy
8.3.1. Excimer Laser
8.3.2. Narrowband Uvb
8.3.3. Puva
8.4. Small Molecules
8.4.1. JAK Inhibitors
8.4.2. PDE4 Inhibitors
8.5. Topicals
8.5.1. Calcineurin Inhibitors
8.5.2. Corticosteroids
8.5.3. Vitamin D Analogues
9. Psoriasis Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Auto-Injector
9.2.2. Pre-Filled Syringe
9.2.3. Vial
9.3. Oral
9.3.1. Capsule
9.3.2. Tablet
9.4. Topical
9.4.1. Cream
9.4.2. Gel
9.4.3. Ointment
10. Psoriasis Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Retail Pharmacy
10.4. Specialty Pharmacy
10.4.1. Home Delivery
10.4.2. in-Clinic Dispensing
11. Psoriasis Therapeutics Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Dermatology Centers
11.4. Hospitals
11.4.1. Secondary
11.4.2. Tertiary
12. Psoriasis Therapeutics Market, by Disease Severity
12.1. Introduction
12.2. Mild
12.3. Moderate
12.4. Severe
13. Psoriasis Therapeutics Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Pediatric
14. Americas Psoriasis Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Psoriasis Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Psoriasis Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Novartis AG
17.3.3. Johnson & Johnson
17.3.4. Eli Lilly and Company
17.3.5. Pfizer Inc.
17.3.6. Amgen Inc.
17.3.7. Bristol-Myers Squibb Company
17.3.8. Incyte Corporation
17.3.9. Merck & Co., Inc.
17.3.10. Sun Pharmaceutical Industries Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PSORIASIS THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. PSORIASIS THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. PSORIASIS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PSORIASIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PSORIASIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PSORIASIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-12/23 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-17 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IL-23 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY EXCIMER LASER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY NARROWBAND UVB, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PUVA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY AUTO-INJECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PRE-FILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY GEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOME DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY IN-CLINIC DISPENSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SECONDARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY TERTIARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL PSORIASIS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES PSORIASIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 95. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 96. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 97. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 98. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 99. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 100. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 102. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 103. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 104. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 105. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 106. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 108. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 109. CANADA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 113. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 114. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 117. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 118. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 119. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 121. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 124. MEXICO PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 174. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 176. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 178. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 180. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 186. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 188. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 189. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 190. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 191. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 193. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 194. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 195. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 197. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 199. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 200. GERMANY PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 201. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 202. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 203. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 204. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 205. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 206. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 208. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 209. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 210. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 212. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 214. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 215. FRANCE PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 216. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 217. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 218. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 219. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 220. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 221. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 232. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 233. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 234. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 235. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 236. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 238. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 239. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 240. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 242. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 245. ITALY PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 247. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 248. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 249. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 250. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 253. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 254. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 255. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 257. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 259. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 260. SPAIN PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 284. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 289. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 290. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 292. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 294. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 296. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 298. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 299. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 300. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 302. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 304. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 305. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 306. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 307. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 308. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 309. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 310. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 311. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 313. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 314. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 315. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 316. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, 2018-2030 (USD MILLION)
TABLE 317. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 319. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 320. DENMARK PSORIASIS THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 321. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 322. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 323. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY PHOTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 324. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY TOPICALS, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 327. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 328. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 329. NETHERLANDS PSORIASIS THERAPEUTICS MARKET SIZE, BY TO

Companies Mentioned

The companies profiled in this Psoriasis Therapeutics market report include:
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Eli Lilly and Company
  • Pfizer Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Incyte Corporation
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 26.08 Billion
Forecasted Market Value ( USD ) by 2030 $ 41.59 Billion
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Psoriasis Drugs Market by Drug Class, Route of Administration, Distribution Channel, Patient Severity - Global Forecast to 2030 - Product Image

Psoriasis Drugs Market by Drug Class, Route of Administration, Distribution Channel, Patient Severity - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Psoriasis Treatment Market by Drug Type, Route of Administration, Disease Type, End-User, Distribution Channel - Global Forecast to 2030 - Product Image

Psoriasis Treatment Market by Drug Type, Route of Administration, Disease Type, End-User, Distribution Channel - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Systemic Psoriasis Therapeutics - Global Strategic Business Report - Product Image

Systemic Psoriasis Therapeutics - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Psoriasis Treatment Market Report and Forecast 2024-2032 - Product Image

Psoriasis Treatment Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Chronic Plaque Psoriasis Market Report 2025 - Product Image

Chronic Plaque Psoriasis Market Report 2025

  • Report
  • 175 Pages
  • Global
From

About the Psoriasis Drugs Market

The Psoriasis Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat psoriasis, a chronic skin condition. Psoriasis is characterized by red, scaly patches on the skin, and can cause itching, burning, and pain. Psoriasis drugs are designed to reduce inflammation, reduce the rate of skin cell growth, and reduce the severity of symptoms. The Psoriasis Drugs market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Amgen, Celgene, Janssen, and Novartis. These companies offer a range of treatments, including topical creams, oral medications, and biologic drugs. Other companies in the market include Sun Pharmaceuticals, Glenmark Pharmaceuticals, and Lupin Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.